AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:21:53 07/12/2023 GMT			5-day change	1st Jan Change
10,131 ^GBX	+0.01%		+0.24%	-9.52%

12:23am	AbbVie to buy drug developer Cerevel for $8.7 billion	RE
12-06	AstraZeneca's Koselugo Now Available in Malaysia for Pneumiatric Patients with Symptomatic Neurofibromatosis Type 1plexiform Neurofibromas	CI

ASTRAZENECA : Gets a Buy rating from Barclays

November 20, 2023 at 03:06 pm

In a research note published by Emily Field, Barclays advises its customers to buy the stock. The target price is unchanged at GBX 13500.

Latest news about AstraZeneca PLC

AbbVie to buy drug developer Cerevel for $8.7 billion	11:23pm	RE
AstraZeneca's Koselugo Now Available in Malaysia for Pneumiatric Patients with Symptomatic Neurofibromatosis Type 1plexiform Neurofibromas	12-06	CI
Altimmune open to partnerships, deals with drugmakers, says CEO	12-05	RE
Anything is possible	12-05
JPMorgan Trims AstraZeneca PT, Affirms Overweight Rating	12-05	MT
Analyst recommendations: Broadcom, Deere & Co, Rio Tinto, Lululemon, Nike...	12-05
Goldman lifts Landsec and British Land	12-05	AN
Wuxi Bio Selloff Extends as Analysts Cut Forecasts	12-05	DJ
ASTRAZENECA : Gets a Buy rating from JP Morgan	12-05	ZD
Roche enters obesity drugs race with $2.7 bln Carmot deal	12-04	RE
GLOBAL MARKETS LIVE : Roche, Uber, Amazon, Spotify, 888...	12-04
AstraZeneca: AI collaboration with Absci	12-04	CF
Model N: A niche positioning	12-04
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca	12-04	DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	12-04	MT
Sector Update: Health Care	12-04	MT
Absci Working With AstraZeneca to Use AI Platform to Discover Oncology Candidate	12-04	MT
Absci Corporation Announces Collaboration with Astrazeneca to Advance Ai-Driven Oncology Candidate	12-04	CI
UK Stocks-Factors to watch on Dec 4	12-04	RE
Roche enters obesity drug market with $2.7 bln Carmot deal	12-04	RE
AstraZeneca, Absci Enter $247 Million Partnership to Develop New Cancer Treatment	12-04	MT
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT	12-03	RE
AstraZeneca ties up with AI biologics company to develop cancer drug - FT	12-03	RE
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy	12-01	RE
Global markets live: Meta, Tesla, BP Plc, Pfizer, General Motors...	12-01

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).

Sector

Pharmaceuticals

Calendar

10/12/2023 - American Society of Hematology Meeting - Abstract Number : 1662

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Moderating our over-optimistic expectations for improved profitability

November 10, 2023 at 05:42 pm

'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

February 09, 2023 at 03:04 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

127.53USD

Average target price

165.55USD

Spread / Average Target

+29.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	-9.52%	198 B $
ELI LILLY AND COMPANY	+61.07%	530 B $
NOVO NORDISK A/S	+44.37%	438 B $
JOHNSON & JOHNSON	-11.34%	377 B $
MERCK & CO., INC.	-4.79%	268 B $
ABBVIE INC.	-9.42%	258 B $
NOVARTIS AG	+0.96%	200 B $
PFIZER, INC.	-43.81%	163 B $
AMGEN INC.	+2.55%	144 B $
SANOFI	-4.15%	117 B $